Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

A Low Dose of Pasireotide Prevents Hypoglycemia in Roux-en-Y Gastric Bypass-Operated Individuals

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Genetic Determinants of Weight Loss After Bariatric Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Bone health in patients with type 2 diabetes treated by Roux-En-Y gastric bypass and the role of diabetes remission

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Impact of Upper Abdominal Pain During Pregnancy Following a Gastric Bypass

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Vagal Blocking for Obesity Control: a Possible Mechanism-Of-Action

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Copeptin, a surrogate marker for arginine vasopressin secretion, is positively associated with glucagon

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Post-bariatric hypoglycemia (PBH) can be a serious complication after Roux-en-Y gastric bypass (RYGB), and treatment with somatostatin analogs has been suggested. We investigated the acute effects of three different doses of pasireotide (75 μg, 150 μg, and 300 μg) on the postprandial glucose metabolism in five RYGB-operated individuals with PBH using a mixed meal test. All three doses prevented hypoglycemia but were associated with a notable increase in postprandial hyperglycemia. Moreover, all doses greatly diminished insulin, C-peptide, and glucagon-like peptide-1 responses. Considering its strong hyperglycemic potential, we suggest that pasireotide should be administered carefully in RYGB-operated individuals with PBH, and if necessary, a 75 μg dose seems sufficient to prevent hypoglycemia.

Original languageEnglish
JournalObesity Surgery
ISSN0960-8923
DOIs
Publication statusE-pub ahead of print - 10 Nov 2019

    Research areas

  • Gastric bypass, Hyperglycemia, Hypoglycemia, Pasireotide, Somatostatin analogs

ID: 58351450